Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis
D. P. Mooney, R. L. Gamelli, M. O'Reilly and J. C. Hebert
Department of Surgery, University of Vermont College of Medicine, Burlington 05405.
Multiple immune defects have been demonstrated following thermal injury,
including defective granulocyte production and function. Recombinant human
granulocyte colony-stimulating factor (rhGCSF) is a regulator of the
myelopoietic system. The effect of rhGCSF administration on survival and on
the myelopoietic system in a murine model of Pseudomonas burn wound sepsis
was investigated. Male BDF1 mice that underwent a 15% total body surface
area burn injury and burn wound seeding with 1 x 10(8) Pseudomonas
aeruginosa organisms demonstrated an improved mean survival time with the
subcutaneous administration of 100 ng of rhGCSF twice a day. Mice that
underwent a similar thermal injury and burn wound seeding with 3 x 10(7) P
aeruginosa organisms demonstrated an augmented myelopoietic response
through the administration of rhGCSF, as represented by significantly
increased white blood cell count, neutrophil count, splenic weight, femoral
marrow cellularity, and femoral marrow granulocyte-macrophage
colony-forming cell count. Myelopoietic augmentation through rhGCSF
administration may serve to decrease the morbidity of septic events
following thermal injury.
